Claritev delivered the quarter its growth narrative needed. The company reported a loss of $3.64 per share, narrower than the $3.68 consensus loss for a 1.1% surprise and a 10.6% improvement from the $4.23 loss a year earlier. The bigger story was the top line. Revenue of $268.3 million beat the $256.7 million consensus by 4.5% and grew 9.1% year over year. That extends a clear acceleration from 5.8% in the first quarter and 6.6% in the second. Management raised full-year revenue guidance for a third straight quarter, to $1.038-$1.043 billion. It also put out a preliminary 2027 revenue view of about $1.1 billion, roughly a year ahead of the March Investor Day plan. The central tension is that the growth case is strengthening faster than the financial cushion beneath it.
The quality of the beat deserves scrutiny. Adjusted EBITDA rose only 4.4% to $162.0 million, less than half the pace of revenue, and margin compressed to 60.4% from 63.1%. Management attributed the squeeze to $20-25 million of go-to-market investment and to one-time revenue comparisons rolling off. The full-year margin is now tracking about 60%, below the original 61-62% target.
On a GAAP basis, operating income roughly doubled to $20.6 million. That still sits far below the $100.9 million interest bill, which keeps the company deep in the red. Adjusted EBITDA also added back $10.3 million of antitrust legal expenses, up from $4.1 million a year ago, plus $8.0 million of transformation costs.
Cash flow went the wrong way. Free cash flow was negative $25.8 million versus negative $16.3 million, as capex climbed to $44.4 million. Unrestricted cash fell to $10.1 million, and revolver borrowings rose to $95 million from $20 million at year-end.
The call explained where the growth is coming from. Claims intelligence revenue growth accelerated from 8.4% in Q1 to roughly 14% in Q2 and 17.1% in Q3, driven by No Surprises Act work. Dispute initiations rose 75% year over year, submitted charges climbed 15%, and identified savings per claim increased 13%. Commercial momentum looks broad. Annual contract value (ACV) bookings are now guided to $115-$125 million for the year, implying 70-90% growth and well above the original $80-$100 million target. The pipeline is up about 60%, and more than half of bookings came from outside the payer market.
The weaker spots are real, however. Payment & Revenue Integrity (PRI) is declining and behind plan, which reverses the Q2 expectation that it would grow this year. Its return to growth has been pushed to 2027, a timeline supported by more than $40 million of trailing PRI ACV with only about 20% converted to revenue. Network revenue fell 5.6%, largely due to a $5.4 million non-recurring comparison.
Bears have legitimate ammunition on concentration and visibility. Much of the acceleration traces to NSA volume tied to a single early-2026 client win, and the effects of the independent dispute resolution (IDR) rules are still settling. One analyst noted that the 2027 outlook implies claims intelligence growth will slow. Management offered no 2027 EBITDA or free cash flow guidance, which matters for a company carrying 7.7x net leverage. The raised full-year free cash flow guide of $10-$20 million also depends on a fourth quarter of $74-$84 million, which management expects to be the strongest in more than four years. After nine months of negative free cash flow, that back-end loading is the number to watch. On the catalyst side, the packaged Medicare Advantage offering, transparency-based pricing built on machine-readable file (MRF) data, and the Clara AI agent extend the product story.
Investor sentiment improved substantially, rising from 0.24 to 0.67, so expectations entered the print noticeably more constructive. Price action told a harsher story. Shares spiked to $42.47 shortly after the August report, then unwound the entire move. They hit a quarterly low of $19.25 on November 5 and closed at $22.71 ahead of the release. That leaves the stock 22.1% below its post-Q2 opening price, 46.5% below the quarter high, and about 10.9% under its 200-day moving average. The trend readings are mixed, with momentum positive while AVWAP remains negative, consistent with a stock that has been sold despite rising estimates.
The bottom line is that Claritev keeps out-executing its own plan on revenue and bookings, and the 2027 pull-forward gives the growth thesis real credibility. Even so, margins are slipping, cash is scarce, leverage is heavy, and growth leans on one NSA-driven engine. The market's steep retreat since August shows investors want proof in cash, not just revenue. A fourth quarter that delivers the promised free cash flow would do more for the setup than another guidance raise.